Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add filters








Language
Year range
1.
Rev. chil. obstet. ginecol ; 79(1): 21-26, 2014. graf, tab
Article in Spanish | LILACS | ID: lil-706554

ABSTRACT

Antecedentes: El lupus eritematoso sistémico (LES) afecta principalmente a mujeres en edad fértil. El embarazo en estas pacientes puede asociarse con múltiples complicaciones. Objetivo: Caracterizar a las embarazadas con LES durante 10 años en el Hospital Clínico Regional de Concepción. Métodos: Se realizó un estudio descriptivo retrospectivo que consistió en la revisión de fichas clínicas. Se analizaron las variables: edad, años de enfermedad desde el diagnóstico, historia obstétrica, presencia de reactivaciones, anticuerpos maternos y complicaciones materno-fetales. Resultados: Durante el periodo de estudio hubo 49 embarazos en 21 pacientes con LES. El 12,2 por ciento terminó en aborto, un 2 por ciento en óbitos, y un total de 43 nacidos vivos. La edad promedio de las pacientes al momento del diagnóstico de LES fue 24,5 años. El 67 por ciento fueron diagnosticadas antes de su primer embarazo. En el total de pacientes el 85,7 por ciento presentaron ANA positivo, 57,1 por ciento antiDNA positivo, 52,4 por ciento aRo positivo y 33,3 por ciento aLa positivo. En los caso de abortos, aRo y aLa se encontraban positivos en 66,7 por ciento. Las anticardiolipinas se encontraban alteradas en 33,3 por ciento de los abortos. Durante el embarazo el 32,6 por ciento tenía LES activo y 34,7 por ciento en el postparto. El 53,5 por ciento de los recién nacidos no tuvieron complicaciones. La complicación más frecuente fue la prematuridad con 55 por ciento. La mortalidad perinatal de la serie fue de 46,5/1000 nacidos vivos (2/43). No hubo muertes maternas. Conclusión: Es importante la educación respecto al embarazo en pacientes con LES. Debemos resaltar en promover que estas pacientes planifiquen el embarazo en periodo de inactividad, y con controles frecuentes para pesquisar precozmente cualquier complicación.


Background: The systemic lupus erythematosus (SLE) affects mainly fertile age women. Pregnancy in these patients can associate with multiple complications. Aims: To characterize the pregnant women with SLE during 10 years in the Hospital Clínico Regional de Concepción, Chile. Methods: We made a retrospective descriptive study which consisted in clinical files revision. The following variables were analyzed: age, years with disease since diagnose, obstetric history, history of reactivation, maternal antibodies and mother-fetus complications. Results: During the time of study there were 49 pregnancies on 21 patients with SLE; 12.2 percent ended in abortion, 2 percent in late fetal death giving a total of 43 living newborn. The average age of these patients at the moment of diagnose of LES was 24.5 years old; 67 percent were diagnosed before their first pregnancy. From the total of patients, 85.7 percent presented positive ANA, 57.1 percent positive antiDNA, positive aRo in 52.4 percent and positive aLa in 33.3 percent. In case of abortions, aRo and aLa were positive in 66.7 percent. Anticardiolipins were altered in 33.3 percent of abortions. During pregnancy 32.6 percent had active SLE, and 34.7 percent post-partum. Among the newborn, 53.5 percent did not have any complications. The most frequent complication was prematurity with a 55 percent. The perinatal mortality was 46.5/1000 lives births (2/43). There were no maternal deaths. Conclusion: It is important to educate about pregnancy in SLE patients. We must emphasize to promote in those patients a planned pregnancy in inactive period and with frequent controls for early diagnose of any complication.


Subject(s)
Humans , Adolescent , Adult , Female , Pregnancy , Young Adult , Pregnancy Complications/epidemiology , Lupus Erythematosus, Systemic/epidemiology , Age Distribution , Chile , Epidemiology, Descriptive , Gestational Age , Retrospective Studies
2.
Rev. ANACEM (Impresa) ; 5(2): 91-94, dic. 2011. graf
Article in Spanish | LILACS | ID: lil-640059

ABSTRACT

INTRODUCCIÓN: El lupus eritematoso sistémico es considerado un factor de riesgo cardiovascular. En estos pacientes es frecuente hallar dislipidemias. La terapia corticoesteroide favorece las alteraciones lipídicas. HIPÓTESIS: Los pacientes con lupus eritematoso sistémico presentan hipercolesterolemia, hipertrigliceridemia o ambos, en mayor proporción que la población general. OBJETIVO: Determinar la prevalencia de dislipidemias en los pacientes diagnosticados de lupus eritematoso sistémico y controlados en el policlínico de reumatología del Hospital Clínico Regional de Concepción. MATERIAL Y MÉTODO: Estudio descriptivo transversal en pacientes diagnosticados de lupus eritematoso sistémico, y que se han controlado durante el 2010 en el policlínico de reumatología. Las variables estudiadas fueron: sexo, edad, hipercolesterolemia, hipertrigliceridemia, dosis/ tiempo de uso de corticoides e hidroxicloroquina. RESULTADOS: Total de pacientes estudiados (n=154), 88,9 por ciento (n=137) mujeres, edad promedio45,6 + 5 años, 40,9 por ciento (n=43) presenta hipertrigliceridemia; 55,2 por ciento (n=58) presenta hipercolesterolemia y 65,9 por ciento (n=100) presenta ambas alteraciones. Pacientes con evolución menor de 10 años: 50 por ciento (n=29) presenta hipercolesterolemia, 34,5 por ciento (n=20) presentaba hipertrigliceridemia; con 11-20 años de evolución: 56,25 por ciento (n=18) presenta hipercolesterolemia.; 43,75 por ciento (n=14) presenta hipertrigliceridemia Con evolución mayor a 20 años: 73,3 por ciento (n=11) presenta hipercolesterolemia; 60 por ciento (n=9) presentaba hipertrigliceridemia Usuarios de corticoides 89 por ciento (n=138) y de hidroxicloroquina 92,4 por ciento (n=142). DISCUSIÓN: La principal alteración es hipercolesterolemia. Pacientes con más años de evolución presentan mayor número de dislipidemias. La mayoría son usuarios de corticoides. Concluimos que la prevalencia de...


INTRODUCTION: Systemic lupus erythematosus is considered a cardiovascular risk factor. Dyslipidemia is commonly found in these patients. Corticosteroid therapy promotes lipid abnormalities. HYPOTHESES: Systemic lupus erythematosus patients with hypercholesterolemia, hypertriglyceridemia, or both, in greater proportion than the general population. OBJECTIVE: To determine the prevalence of dyslipidemia in patients diagnosed with systemic lupus erythematosus and monitored at the clinic of rheumatology, Hospital Clínico Regional Concepción. MATERIAL AND METHOD: A retrospective cross sectional in patients diagnosed with systemic lupus erythematosus and have controlled the last year in the Hospital Clínico Regional Concepción. The variables studied were: sex, age, hypercholesterolemia, hypertriglyceridemia, dose/duration of use of corticosteroids and hydroxichloroquine. RESULTS: Of all patients studied (n=154), 88.9 percent (n=137) women, mean age 45.6 +/- 5 years, 40.9 percent (n=43) presents hypertriglyceridemia, 55.2 percent (n=58) presented hypercholesterolemia presented and 65.9 percent (n=100) presented both alterations. Patients with minor changes 10 years: 50 percent (n=29) presents hypercholesterolemia; 34.5 percent (n=20) had hypertriglyceridemia. With11-20 years of evolution: 56.25 percent (n=18) presents hypercholesterolemia;45.75 percent (n=14) has hypertriglyceridemia. With over 20years of evolution: 73.3 percent (n=11) has hypercholesterolemia; 60 percent(n=9) showed hypertriglyceridemia. Steroids users 89 percent (n=138)and 92.4 percent (n=142) using hixychloroquine. DISCUSSION: The main alteration is hypercholesterolemia. Patients with more years of evolution have a greater number of dyslipidemia than others patients. Most are steroid users. We conclude that the prevalence of dyslipidemia is more common in systemic lupus erythematosus patients than the general population...


Subject(s)
Humans , Male , Adult , Female , Middle Aged , Dyslipidemias/epidemiology , Lupus Erythematosus, Systemic/complications , Chile , Cross-Sectional Studies , Dyslipidemias/etiology , Hypercholesterolemia/epidemiology , Hypertriglyceridemia/epidemiology , Prevalence , Retrospective Studies , Time Factors
3.
Rev. méd. Chile ; 124(2): 217-24, feb. 1996. tab
Article in Spanish | LILACS | ID: lil-173324

ABSTRACT

Seronegative arthritides are a heterogeneous group of diseases that includes rheumatoid arthritis with negative rheumatoid factor. Between 1980 and 1984 we studied 38 patients with seronegative arthritis. Thirty of these patients were reassessed in 1994 after 9 or 20 years of evolution. Seventeen patients had a diagnosis of seronegative rheumatoid arthritis; this diagnosis was maintained in 12, changed to seropositive rheumatoid arthritis in 3, to psoriatic arthritis in 1 and connective tissue disease in 1. Thirteen patients had a diagnosis of undifferentiated arthritis; in 1994 the diagnosis was maintained in 3, 7 patients were diagnosed as having a sppondyloarthropathy, 2 as having a reactive arthritis and 1 as having a connective tissue disease. In 1994, nine patients fulfilled the 1991 criteria for spondyloarthritis and 6 of these did so on admission. Six of 12 patients with seronegative rheumatoid arthritis had an active disease or used antiinflammatory drugs and 64 percent had erosions on hand X ray examination. These figures are in contrast with the enigm evolution classically attributed to this disease and agree with recent reports. The usefulness of classification criteria for rheumatoid arthritis and spondyloarthritis in the initial assessment of patients with seronegative arthritis is emphasized


Subject(s)
Humans , Male , Female , Arthritis/blood , Arthritis, Rheumatoid/diagnosis , Rheumatoid Factor/blood , Serologic Tests , Follow-Up Studies , Prognosis
SELECTION OF CITATIONS
SEARCH DETAIL